List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. Therapeutic Administration of Suppressor of Cytokine Signaling Mimetics to Ameliorate Type Diabetes

    SBC: ONEVAX, LLC            Topic: NIAID

    Type Diabetes T D results from a breakdown of self tolerance that is characterized by immune cell mediated destruction of the insulin producing cells in the pancreas Ultimately glucose metabolism is interrupted resulting in the development of life threatening complications such as heart disease and renal failure T D affects an estimated million Americans with more than new patie ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Probabilistic Modeling for Software Guided Radiotherapy Patient Plan QA

    SBC: SUN NUCLEAR CORP.            Topic: 103

    Errors in the planning and delivery of radiation therapy can result in inferior outcomes for patients The magnitude of this problem is now well appreciated from cooperative group trials and other sources At present however there are few concrete tools to reduce the chance of plan errors passing undetected Current practice uses a variety of error mitigation means such as human inspection of th ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Identification of Small Molecule Amyloid Beta Peptide Reducing Agent

    SBC: Smart Biomolecules, Inc.            Topic: NIA

    Alzheimer s disease AD is a multifactorial heterogeneous and enormously complex disorder characterized by progressive intellectual deterioration Although remarkable advances have been made in unraveling the biological basis of the disease in the last two decades that immense knowledge has not been translated in to successful therapy With the failure of secretase inhibitors at the clinical tr ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Developing a novel therapy for diabetic retinopathy

    SBC: Everglades Biopharma, LLC            Topic: W

    Project Summary Diabetic retinopathy DR is a leading cause of vision loss affecting about million people worldwide A major breakthrough in DR therapy is the recent approval of vascular endothelial growth factor VEGF inhibitors However anti VEGF therapy has limited efficacy with a number of side effects The critical barrier is how to identify other angiogenic targets for alternative or ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. A Randomized Blinded Placebo Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell LMSC Therapy for Treating The Metabolic Syndrome

    SBC: Longeveron LLC            Topic: NIA

    The metabolic syndrome MetS is a cluster of factors that increases the risks for cardiovascular disease type diabetes mellitus and mortality and currently affects andgt of US adults MetS is associated with endothelial dysfunction decreased circulating endothelial progenitor cells EPCs and a pro inflammatory state We have made the exciting discovery that therapy with allogeneic me ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Receptors, Ligands, and Catalysts on Demand using Expanded Genetic Alphabets

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: 100

    DESCRIPTION provided by applicant Technology to deliver molecules andquot on demandandquot that bind to targets or catalyze reactions of a technologistandapos s choosing would have enormous commercial value in research manufacturing and medicine Thus this has been a andquot holy grailandquot of molecular science for a half century Even today chemical theory is inadequate to support de ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. RSK3 Anchoring Disruptor Therapy for Heart Failure

    SBC: ANCHORED RSK3 INHIBITORS, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Pathological cardiac remodeling including myocyte hypertrophy and apoptosis and myocardial interstitial fibrosis constitutes a common pathway to heart failure in disease Despite current pharmacologic therapy and other advances that attenuate remodeling mortality due to heart failure remains high New more effective therapeutic options are desperately neede ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Novel piperazine tethered thiazole compounds as antimalarials

    SBC: Smart Biomolecules, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant In spite of all the advances in molecular medicine malaria still afflicts about million people worldwide and half of the world population is at rik The disease causes nearly million deaths each year mostly children Unfortunately the prospects for control of malaria by chemotherapy have been seriously compromised by the emergence of resistance to all av ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Targeting CD137L to MC1R-Expressing Melanoma Cells and Tumors.

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    DESCRIPTION provided by applicant There are specific high affinity ligands for receptors found on many cancers that have been investigated as imaging probes and we believe that we should try to enhance immunotherapy by using these ligands to deliver immune effectors to the cancer microenvironment Melanoma is among the most immunogenic tumors known and so that disease is an excellent test bed f ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Simple Inexpensive Assay for Five Common HIV Resistance Mutations

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: NIAID

    DESCRIPTION provided by applicant Only a few inexpensive drugs can be used in the developing world for the treatment of AIDS Several of these target the HIV reverse transcriptase RT Accordingly patient therapy with these drugs often fails when the gene encoding RT undergoes mutation Thus the WHO recently reported that after months of treatment with anti RT drugs patients most often r ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government